<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601742</url>
  </required_header>
  <id_info>
    <org_study_id>HGNAE-09</org_study_id>
    <nct_id>NCT02601742</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute</brief_title>
  <official_title>Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute in Mexican Children: Randomized Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Naval de Alta Especialidad - Escuela Medico Naval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Naval de Alta Especialidad - Escuela Medico Naval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute diarrhea is the third cause of infant mortality in the world causing 15% of all deaths&#xD;
      in children under 5 years and is responsible for nearly 1.4 million deaths in developing&#xD;
      countries. It is considered a self-limiting disease and to this problem the recommendation of&#xD;
      the World Health Organization (WHO) is the administration of zinc with low osmolarity oral&#xD;
      dehydration salts for a period of 10-14 days which reduces the severity of the episode.&#xD;
&#xD;
      In Mexico COFEPRIS believes the zinc salt as a food supplement and not a drug and the above&#xD;
      problem is presented in terms of prescribing and access of this salt to the general&#xD;
      population. In Mexico the investigators have the provision and accessibility of low&#xD;
      osmolarity oral dehydration salts supplemented with adequate doses of zinc, which is&#xD;
      inexpensive for the general population and offering a solution in terms of supply and&#xD;
      management.&#xD;
&#xD;
      The purpose of the study involves the evaluation Pedialyte diarrhea in the treatment of acute&#xD;
      diarrhea in children under 5 years. The investigator sconsider the use of Pedialyte diarrhea&#xD;
      eases their access to the population in general and it is low cost compared with the zinc&#xD;
      salt that is sold only in specialized pharmacies under strict medical prescription Objective:&#xD;
      Compare the duration of symptoms of acute diarrhea in the treatment with low osmolarity oral&#xD;
      rehydration salts (Pedialyte) vs treatment of low osmolarity oral rehydration supplemented&#xD;
      with zinc (Pedialyte diarrhea) Study Desing: Double blind, randomized, controlled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be conducted a randomized controlled double-blind in the Emergency service of the&#xD;
      Naval General Hospital of High Specialty in the Mexico City. The period of patient inclusion&#xD;
      in the study is October 2015 to November 2016.&#xD;
&#xD;
      The patients selections is the children between 6 months and 5 years who come to the&#xD;
      emergency room with symptoms of acute diarrhea with up to 48 hours of starting the disease,&#xD;
      it will proceed to questioning and to assess vital signs and thorough physical examination&#xD;
      for determine the degree of dehydration, nutritional status and rule out diagnosis of&#xD;
      abdominal pathology emergency.&#xD;
&#xD;
      Selection criteria Inclusion&#xD;
&#xD;
        -  Patients 6 months to 5 years old with acute diarrhea&#xD;
&#xD;
        -  Patients in their first 48 hours of onset diarrhea&#xD;
&#xD;
        -  Dehydration mild to moderate according to WHO clinical scale&#xD;
&#xD;
        -  Both sexes&#xD;
&#xD;
        -  Outpatients&#xD;
&#xD;
      Exclusion&#xD;
&#xD;
        -  Patients with vomit (10 or more)&#xD;
&#xD;
        -  Hemodynamic Instability&#xD;
&#xD;
        -  Dehydration severe&#xD;
&#xD;
        -  Patients with heart disease&#xD;
&#xD;
        -  Patients with a history of prematurity.&#xD;
&#xD;
        -  Patients with chronic diarrhea&#xD;
&#xD;
        -  Patients whose parents refuse to provide written informed consent&#xD;
&#xD;
        -  Patients who do not comply with treatment correctly&#xD;
&#xD;
        -  Patients with suspected surgical pathology&#xD;
&#xD;
      Elimination&#xD;
&#xD;
        -  Patients with severe dehydration&#xD;
&#xD;
        -  Patients in whom the parents decline for informed consent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bowel movements per day</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Diarrhea</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Zinc group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pedialyte oral electrolyte solution, 330 ml per day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zinc group</intervention_name>
    <description>Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days</description>
    <arm_group_label>Zinc group</arm_group_label>
    <other_name>Pedialyte diarrhea 45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Pedialyte oral electrolyte solution, 330 ml per day for 7 days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Pedialyte SR 45</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 6 months to 5 years old with acute diarrhea&#xD;
&#xD;
          -  Patients in their first 48 hours of onset diarrhea&#xD;
&#xD;
          -  Dehydration mild to moderate according to WHO clinical scale&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with vomit (10 or more)&#xD;
&#xD;
          -  Hemodynamic Instability&#xD;
&#xD;
          -  Severe dehydration&#xD;
&#xD;
          -  Patients with heart disease&#xD;
&#xD;
          -  Patients with a history of prematurity.&#xD;
&#xD;
          -  Patients with chronic diarrhea&#xD;
&#xD;
          -  Patients whose parents refuse to provide written informed consent&#xD;
&#xD;
          -  Patients who do not comply with treatment correctly&#xD;
&#xD;
          -  Patients with suspected surgical pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María del Carmen Yebra Cano, Medicina</last_name>
    <role>Principal Investigator</role>
    <affiliation>Secretaria de Marina-Armada de México (Mexican Navy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María del Carmen Yebra Cano, Medicina</last_name>
    <phone>5585315297</phone>
    <email>melitacar@hotmail.com</email>
  </overall_contact>
  <link>
    <url>http://www.insp.mx</url>
    <description>Encuesta Nacional de Salud y Nutrición 2012</description>
  </link>
  <reference>
    <citation>Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012 Jun 9;379(9832):2151-61. doi: 10.1016/S0140-6736(12)60560-1. Epub 2012 May 11. Erratum in: Lancet. 2012 Oct 13;380(9850):1308.</citation>
    <PMID>22579125</PMID>
  </reference>
  <reference>
    <citation>Gupta GR. Tackling pneumonia and diarrhoea: the deadliest diseases for the world's poorest children. Lancet. 2012 Jun 9;379(9832):2123-4. doi: 10.1016/S0140-6736(12)60907-6.</citation>
    <PMID>22682449</PMID>
  </reference>
  <reference>
    <citation>Aurelio Mejia y cosl., Analisis de costo beneficio de la suplementación con Zinc en el tratamiento de la diarrea aguda en niños menores de 5 años en Colombia, publicado en ESPGHAN 2015</citation>
  </reference>
  <reference>
    <citation>Scrimgeour, A.; Condlin, M.; Otieno, L.; Bovill, M. Zinc intervention strategies: Costs and health benefits. In Nutrients, Dietary Supplements, and Nutriceuticals; Gerald, J.K., Watson, R.R., Preedy, V.R., Eds.; Humana Press: 201</citation>
  </reference>
  <reference>
    <citation>WHO/UNICEF. Joint Statement on the Clinical Management of Acute Diarrhoea; UNICEF: 2004</citation>
  </reference>
  <reference>
    <citation>Benguigui Y, Bernal C, Figueroa D, eds. Manual de Tratamiento de la Diarrea en Nin˜os. Washington, DC: Panamerican Health Organization/ Organización Panamericana de la Salud; 2008</citation>
  </reference>
  <reference>
    <citation>Malek MA, Curns AT, Holman RC, Fischer TK, Bresee JS, Glass RI, Steiner CA, Parashar UD. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics. 2006 Jun;117(6):1887-92.</citation>
    <PMID>16740827</PMID>
  </reference>
  <reference>
    <citation>Majowicz SE, McNab WB, Sockett P, Henson TS, Doré K, Edge VL, Buffett MC, Fazil A, Read S, McEwen S, Stacey D, Wilson JB. Burden and cost of gastroenteritis in a Canadian community. J Food Prot. 2006 Mar;69(3):651-9.</citation>
    <PMID>16541699</PMID>
  </reference>
  <reference>
    <citation>Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD005436. doi: 10.1002/14651858.CD005436.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(1):CD005436.</citation>
    <PMID>22696352</PMID>
  </reference>
  <reference>
    <citation>Liberato SC, Singh G, Mulholland K. Zinc supplementation in young children: A review of the literature focusing on diarrhoea prevention and treatment. Clin Nutr. 2015 Apr;34(2):181-8. doi: 10.1016/j.clnu.2014.08.002. Epub 2014 Aug 13. Review.</citation>
    <PMID>25176404</PMID>
  </reference>
  <reference>
    <citation>Dr Rul L. Riveron Corteguera, Fisiopatología de la diarrea aguda, Hospital pediátrico docente de la Habana 2009</citation>
  </reference>
  <reference>
    <citation>King JC, Shames DM, Woodhouse LR. Zinc homeostasis in humans. J Nutr. 2000 May;130(5S Suppl):1360S-6S. doi: 10.1093/jn/130.5.1360S. Review.</citation>
    <PMID>10801944</PMID>
  </reference>
  <reference>
    <citation>Baqui AH, Black RE, El Arifeen S, Yunus M, Chakraborty J, Ahmed S, Vaughan JP. Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial. BMJ. 2002 Nov 9;325(7372):1059.</citation>
    <PMID>12424162</PMID>
  </reference>
  <reference>
    <citation>Fischer Walker CL, Fontaine O, Young MW, Black RE. Zinc and low osmolarity oral rehydration salts for diarrhoea: a renewed call to action. Bull World Health Organ. 2009 Oct;87(10):780-6.</citation>
    <PMID>19876545</PMID>
  </reference>
  <reference>
    <citation>Maggini S, Wenzlaff S, Hornig D. Essential role of vitamin C and zinc in child immunity and health. J Int Med Res. 2010 Mar-Apr;38(2):386-414. Review.</citation>
    <PMID>20515554</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zinc</keyword>
  <keyword>Duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

